Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96

Global distribution and prevalence of hepatitis C virus genotypes. Hepatology (2014) 3.95

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA (2014) 3.15

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80

Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut (2014) 2.33

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois. Gastroenterol Hepatol (N Y) (2015) 2.20

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07

Hepatitis C. Lancet (2015) 1.95

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology (2015) 1.48

HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology (2014) 1.46

Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis (2013) 1.39

Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc (2014) 1.38

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37

The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33

Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29

The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One (2014) 1.25

Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22

HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat (2014) 1.16

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology (2016) 1.12

Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol (2013) 1.12

Treatment Options in Hepatitis C. Dtsch Arztebl Int (2017) 1.10

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology (2015) 1.10

Emerging therapies for the treatment of hepatitis C. EMBO Mol Med (2014) 1.09

Cell and tissue engineering for liver disease. Sci Transl Med (2014) 1.08

Emerging therapies for hepatitis C. Gut Liver (2014) 1.07

HCV treatment--no more room for interferonologists? N Engl J Med (2013) 1.03

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon (2016) 1.02

ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Res (2015) 1.02

Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med (2014) 1.02

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol (2016) 1.02

High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol (2014) 1.02

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat (2014) 1.01

Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00

Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis (2014) 0.99

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog (2014) 0.98

Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol (2014) 0.98

Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98

Advances in hepatitis C therapy: What is the current state - what come's next? World J Hepatol (2016) 0.98

Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin. Open Forum Infect Dis (2014) 0.97

Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97

The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol (2013) 0.96

Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96

APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96

Hepatitis C virus genetic variability and evolution. World J Hepatol (2015) 0.96

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med (2014) 0.95

Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother (2014) 0.94

Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94

Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther (2015) 0.93

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol (2014) 0.93

A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York. Gastroenterol Hepatol (N Y) (2014) 0.92

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses (2015) 0.92

The new era of hepatitis C virus therapy. Saudi J Gastroenterol (2015) 0.91

New approaches in the treatment of hepatitis C. World J Gastroenterol (2016) 0.90

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1-5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNAPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDWeill Cornell Medical CollegeNew York, New York. Gastroenterol Hepatol (N Y) (2014) 0.90

Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol (2014) 0.90

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol (2015) 0.89

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One (2014) 0.89

Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis (2015) 0.89

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses (2015) 0.89

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol (2016) 0.88

Sofosbuvir, a Significant Paradigm Change in HCV Treatment. J Clin Transl Hepatol (2015) 0.88

New treatment strategies for hepatitis C infection. World J Hepatol (2015) 0.88

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87

Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PLoS One (2014) 0.87

The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol (2015) 0.86

Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol (2015) 0.86

All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci (2014) 0.86

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med (2014) 0.86

Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS One (2017) 0.85

Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother (2014) 0.85

A brighter future in the fight against hepatitis. Nat Med (2013) 0.85

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol (2015) 0.85

Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol (2014) 0.85

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clin Infect Dis (2016) 0.84

Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report. J Gastrointest Oncol (2015) 0.84

Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One (2015) 0.84

Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother (2014) 0.84

Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.84

Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open (2014) 0.84

Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol (2016) 0.84

Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore) (2015) 0.84

Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm (2016) 0.83

Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol (2014) 0.83

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. AIDS Patient Care STDS (2015) 0.83

Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J Transl Med (2014) 0.83

CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol (2015) 0.83

The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. PLoS One (2015) 0.83

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Viruses (2015) 0.83

Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol (2015) 0.83

Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 37.89

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

The genome sequence of the malaria mosquito Anopheles gambiae. Science (2002) 20.36

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33

Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

The Chlamydomonas genome reveals the evolution of key animal and plant functions. Science (2007) 11.15

Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48

Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Comparative genome and proteome analysis of Anopheles gambiae and Drosophila melanogaster. Science (2002) 9.43

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13

The Physcomitrella genome reveals evolutionary insights into the conquest of land by plants. Science (2007) 8.12

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (2010) 6.52

Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology (2005) 5.33

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64

Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48

Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09

Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07

NeuPSIG guidelines on neuropathic pain assessment. Pain (2010) 4.04

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96

Raxibacumab for the treatment of inhalational anthrax. N Engl J Med (2009) 3.91

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69

The Ectocarpus genome and the independent evolution of multicellularity in brown algae. Nature (2010) 3.60

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57

Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46